Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
First generation Japanese; subject was born in Japan and has not lived outside of Japan for \> 10 years, and subject can trace maternal and paternal Japanese ancestry.
Histologically confirmed aggressive/indolent DLBCL, FL, MZL, or MCL.
Previously received at least 1 prior line of systemic therapy with documented progression, and there is no further effective standard anticancer therapy available.
Willing to undergo an incisional or excisional lymph node or tissue biopsy or to provide a lymph node or tissue biopsy from the most recent available archival tissue.
Life expectancy \> 3 months.
Eastern Cooperative Oncology Group performance status of 0 to 2.
Adequate hematologic, hepatic, and renal function.
You may not be if
Evidence of transformed non-Hodgkin's lymphoma histologies.
History of central nervous system lymphoma (either primary or metastatic) or leptomeningeal disease.
Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan-phosphatidylinositol 3 kinase (PI3K) inhibitor.
Allogeneic stem cell transplant within the last 6 months or autologous stem cell transplant within the last 3 months before the date of the first dose of study drug.
Active graft-versus-host disease.
History of stroke or intracranial hemorrhage within 6 months of study drug administration.
Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment or exposure to a live vaccine within 30 days of the date of the first dose of study drug.
Known human immunodeficiency virus infection.
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
